Key Financial Figures - Q1FY27 (Quarter Ended June 30, 2026)

  • Total Income: ₹650.1 crores (vs. ₹300.6 crores in Q1FY26, representing 16.3% YoY growth)
  • EBITDA: ₹231.1 crores
  • EBITDA Margin: 35.5%
  • Gross Margin: 61.2% (vs. 55.3% in Q1FY26)
  • Profit After Tax: ₹147.4 crores (vs. ₹13.7 crores in Q1FY26)
  • Earnings Per Share: ₹114.9 per share

Operational Highlights

  • Commercial CMS projects contributed the majority share of revenue and were primary growth drivers
  • Working capital days improved significantly from 137 days at FY26-end to 84 days in Q1FY27
  • Cash outflow of ₹121.6 crores towards capital expenditure during Q1FY27
  • Approved capital investments of approximately ₹203 crores, with ₹196 crores earmarked for strategic growth initiatives
  • Total approved capex of ₹1,460 crores over last 13 quarters, with ₹870 crores spent to date

Business Performance Details

GDS Business Performance

  • Key contributing products: Ezetimibe, Mirtazapine, Escitalopram, and Aripiprazole
  • Focus on expanding differentiated product portfolio and increasing presence in key markets (Brazil, Japan, South Korea, Turkey)
  • Pursuing life cycle management opportunities with innovators

CMS Business Performance

  • Majority revenues from top commercial products
  • Encouraging order book from pipeline molecules expected to materialize over next few quarters
  • Healthy engagement across both development and commercial programs
  • Customer conversations increasingly capability-led rather than project-specific

Strategic Initiatives and Investments

Peptide Business

  • Peptide manufacturing plant commissioning scheduled for September 2026
  • Multiple projects lined up at various stages
  • Customer interest growing even before facility ramp-up
  • Module 1 utilization visibility improving

Strategic Collaboration

  • Partnership with Gland Pharma for sterile API manufacturing
  • Combines Neuland's complex API expertise with Gland's sterile manufacturing capabilities
  • Asset-light arrangement focusing on niche generic category products
  • Creates differentiated platform in sterile APIs

Management Commentary and Outlook

  • Q1FY27 performance broadly in line with expectations
  • Reiterated long-standing view of business unevenness across quarters
  • Maintain 20% growth ambition for FY27 and FY28
  • Confidence in medium-term trajectory based on customer interest, opportunities, and capabilities
  • Focus on execution, customer service, operational excellence, and long-term value creation

Capacity Expansion and Future Plans

  • Capacity expansion primarily at Unit 1
  • Evaluating acquisition of adjacent lands for short-term expansion
  • Planning additional manufacturing sites with larger land parcels for long-term growth
  • Future investments expected to be quantitatively larger and qualitatively different (newer modalities, possible geographic diversification)

Risk Factors Mentioned

  • Geopolitical developments
  • Regulatory timelines
  • Customer ordering patterns
  • Broader macroeconomic conditions
  • Inherent quarterly variability in business performance

Corporate Governance

  • Clarification provided regarding Q4FY26 transcript editing concern
  • Full unedited audio of earnings calls published on company website
  • Written transcripts slightly edited for readability by external agency

Webcast Questions Addressed

  • Margin profile considered comfortable with expectation of 25%+ EBITDA margins long-term
  • ROCE may dip during expansion phases due to capital deployment
  • Peptide facility has order visibility with multiple projects ready
  • Facility located in FDA-approved manufacturing site, though subject to future FDA audit